利用治疗性纳米粒对抗 P-糖蛋白介导的多药耐药性。
Combating P-glycoprotein-mediated multidrug resistance using therapeutic nanoparticles.
机构信息
Department of Analytical Chemistry, School of Chemistry and Chemical Engineering, Shandong University, 27, South Shanda Road, 250100, Jinan, Shandong, China.
出版信息
Curr Pharm Des. 2013;19(37):6655-66. doi: 10.2174/1381612811319370009.
The development of multidrug resistance (MDR) to chemotherapy is a major obstacle for the successful treatment of cancer. A number of mechanisms have been postulated to account for MDR in cancer. The most common and best-studied mechanism of resistance is mediated through the drug efflux protein P-glycoprotein (P-gp), which is overexpressed in drug-resistant cancer cells and is responsible for the removal of many chemotherapeutic agents. Therapeutic nanoparticles (NPs) have emerged as an innovative and promising option to combat P-gp-mediated MDR and have shown enhanced therapeutic efficacy and reduced toxicity compared to their small molecule counterparts. This review focuses on recent studies using therapeutic NPs to circumvent P-gp-mediated MDR in cancer therapy. The advantages and strategies by which therapeutic NPs were used to overcome P-gp-mediated MDR in cancer are discussed.
多药耐药（MDR）的发展是癌症化疗成功治疗的主要障碍。已经提出了许多机制来解释癌症中的 MDR。最常见和研究最多的耐药机制是通过药物外排蛋白 P-糖蛋白（P-gp）介导的，P-糖蛋白在耐药癌细胞中过度表达，负责清除许多化疗药物。治疗性纳米颗粒（NPs）作为一种创新和有前途的选择，已被用于对抗 P-gp 介导的 MDR，与小分子相比，它们显示出增强的治疗效果和降低的毒性。本综述重点介绍了最近使用治疗性 NPs 来克服癌症治疗中 P-gp 介导的 MDR 的研究。讨论了治疗性 NPs 用于克服癌症中 P-gp 介导的 MDR 的优势和策略。
Zotero 插件